Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$ 

N		
	of entity erium Limited	
Turk	Endin Ennice	
ABN		
24 60	05 352 510	
We (t	he entity) give ASX the followin	g information.
	1 - All issues ust complete the relevant sections (attack	
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Ordinary shares
2	Number of *securities issued or	a 6ar 66 fully paid and pamy shares
2	to be issued (if known) or maximum number which may be issued	2,621,367 fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

**Principal** terms of the 3 +securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares as per the Company's Employee Share Plans. These loan-funded shares\* are awarded to directors as a long term incentive approved by shareholders at the 2016 AGM.

#### \*Loan-funded shares

821,367 loan-funded shares have been issued as new equity of Adherium Limited to Adherium ESP Trustee Limited, which holds shares on behalf of the New Zealand participants to the plan. 1,800,000 loan-funded shares are issued to other participants subject to restriction agreements correlating with vesting and loan repayment terms.

Adherium Limited has loaned the participants a total of \$1,310,683.50 (2,621,367 shares at \$0.50 per share) to purchase the shares (Loans).

The participants to the plan will be entitled to the shares one-third annually over a three-year employment period. If they choose to take title to the shares once vested, the loan must be repaid to the Company immediately in cash or loan-funded shares.

The Loans mature on 8 November 2021, at which point the Loan must either be repaid in full, or the entitlement to the loan-funded shares will lapse and they will be cancelled.

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
	merest payment	
5	Issue price or consideration	2,621,367 fully paid ordinary shares issued pursuant to the Company's Employee Share Plans at a price per share of A\$0.50.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issue of fully paid ordinary shares pursuant to the Company's Employee Share Plans as a long term incentive as approved by shareholders.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	No
	comply with section of	
6b	The date the security holder resolution under rule 7.1A was passed	Not applicable
6с	Number of *securities issued without security holder approval under rule 7.1	Not applicable

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	Not applicable	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Not applicable	
6f	Number of *securities issued under an exception in rule 7.2	Not applicable	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Not applicable	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	25,744,540	
7	<sup>+</sup> Issue dates	8 November 2016	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	o November 2010	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	136,307,464	Ordinary shares

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

\* Note: These shares, and in relation to options any resulting shares on exercise, are being not quoted on ASX they as are restricted securities until the particular dates specified.

Number	+Class
35,322,804*	Ordinary shares (* 26 August 2017)
173,238	Options exercisable at \$0.075268 expiring 31 March 2017
344,458*	Options exercisable at \$0.075268 expiring 31 March 2017 (* 26 August 2017)
346,476	Options exercisable at \$0.075268 expiring 31 March 2018
254,045*	Options exercisable at \$0.075268 expiring 31 March 2018 (* 26 August 2017)
433,095	Options exercisable at \$0.075268 expiring 31 March 2019
365,966*	Options exercisable at \$0.075268 expiring 31 March 2019 (* 26 August 2017)
324,639	Options exercisable at \$0.075268 expiring 31 March 2020
265,253*	Options exercisable at \$0.075268 expiring 31 March 2020 (* 26 August 2017)
173,238*	Options exercisable at \$0.134039 expiring 31 March 2020 (* 26 August 2017)
217,214*	Options exercisable at \$0.134039 expiring 30 November 2020 (* 26 August 2017)
692,952	Options exercisable at \$0.134039 expiring 16 December 2020
1,039,428*	Options exercisable at \$0.134039 expiring 1 January 2021 (* 26 August 2017)
259,857	Options exercisable at \$0.134039 expiring 24 March 2021

<sup>+</sup> See chapter 19 for defined terms.

173,238*	Options exercisable at \$0.134039 expiring 31 March 2022 (* 26 August 2017)
1,400,000*	Options exercisable at \$0.665 from one year after date of corporate advisory agreement and expiring three years after date of corporate advisory agreement (* 26 August 2017)

Dividend policy (in the case of a trust, distribution policy) on the 10 increased capital (interests)

#### Part 2 - Pro rata issue

Is security holder approval required?	Not applicable
Is the issue renounceable or non-renounceable?	Not applicable
Ratio in which the *securities will be offered	Not applicable
<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	Not applicable
<sup>+</sup> Record date to determine entitlements	Not applicable
Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable
Policy for deciding entitlements in relation to fractions	Not applicable
	required?  Is the issue renounceable or non-renounceable?  Ratio in which the *securities will be offered  *Class of *securities to which the offer relates  *Record date to determine entitlements  Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?  Policy for deciding entitlements

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer	Not applicable
	documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	Not applicable
20	Names of any underwriters	Not applicable
21	Amount of any underwriting fee or commission	Not applicable
22	Names of any brokers to the issue	Not applicable
23	Fee or commission payable to the broker to the issue	Not applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable
28	Date rights trading will begin (if applicable)	Not applicable
29	Date rights trading will end (if applicable)	Not applicable

<sup>+</sup> See chapter 19 for defined terms.

30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable
32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not applicable
33	<sup>+</sup> Issue date	Not applicable
	<b>3 - Quotation of securitie</b> d only complete this section if you are a Type of *securities (tick one)	
34 (a)		<i>t</i> ,
` /		
(b)	All other <sup>+</sup> securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entitie	es that have ticked box 34(a)	
Addit	ional securities forming a nev	w class of securities
Tick to docume	indicate you are providing the informa nts	tion or
35		securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36		y securities, a distribution schedule of the additional umber of holders in the categories

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

	100,001 and over			
37	A copy of any trust deed for the additional *securities			
Entitie	es that have ticked box 34(b)			
38	Number of *securities for which *quotation is sought			
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought			
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?			
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment			
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)			
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)	Number	+Class	

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 8 November 2016

Print name: Rob Turnbull, CFO & Joint Company Secretary

== == == ==

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	141,883,781	
<ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid +ordinary securities cancelled during that 12 month period</li> </ul>	2,557,504 shares issued on exercise of employee options 26 August 2015 to 7 June 2016  6,778,640 shares issued under the Adherium Employee Share Plans 16 May 2016  1,742,879 shares issued under the Adherium Employee Share Plans 23 August 2016  16,046,097 shares issued 26 July 2016 - shareholder approval received at 2016 AGM 2,621,367 shares issued under the Adherium Employee Share Plans 8 November 2016	
"A"	171,630,268	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	25,744,540	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:		
Under an exception in rule 7.2		
• Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	Nil	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	B"] to calculate remaining	
"A" x 0.15	25,744,540	
Note: number must be same as shown in Step 2		
Subtract "C"	Nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	25,744,540	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.